PL3447051T3 - Method for preparing tyrosine kinase inhibitor and derivative thereof - Google Patents
Method for preparing tyrosine kinase inhibitor and derivative thereofInfo
- Publication number
- PL3447051T3 PL3447051T3 PL17788792T PL17788792T PL3447051T3 PL 3447051 T3 PL3447051 T3 PL 3447051T3 PL 17788792 T PL17788792 T PL 17788792T PL 17788792 T PL17788792 T PL 17788792T PL 3447051 T3 PL3447051 T3 PL 3447051T3
- Authority
- PL
- Poland
- Prior art keywords
- derivative
- tyrosine kinase
- kinase inhibitor
- preparing tyrosine
- preparing
- Prior art date
Links
- 150000003667 tyrosine derivatives Chemical class 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610274566 | 2016-04-28 | ||
| PCT/CN2017/082164 WO2017186140A1 (en) | 2016-04-28 | 2017-04-27 | Method for preparing tyrosine kinase inhibitor and derivative thereof |
| EP17788792.4A EP3447051B1 (en) | 2016-04-28 | 2017-04-27 | Method for preparing tyrosine kinase inhibitor and derivative thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3447051T3 true PL3447051T3 (en) | 2022-03-14 |
Family
ID=60160713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17788792T PL3447051T3 (en) | 2016-04-28 | 2017-04-27 | Method for preparing tyrosine kinase inhibitor and derivative thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10793548B2 (en) |
| EP (1) | EP3447051B1 (en) |
| JP (1) | JP6947749B2 (en) |
| CN (1) | CN108290867B (en) |
| BR (1) | BR112018071617A2 (en) |
| CA (1) | CA3021471A1 (en) |
| DK (1) | DK3447051T3 (en) |
| ES (1) | ES2903416T3 (en) |
| HU (1) | HUE057402T2 (en) |
| PL (1) | PL3447051T3 (en) |
| PT (1) | PT3447051T (en) |
| TW (1) | TWI739825B (en) |
| WO (1) | WO2017186140A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108314639B (en) * | 2018-05-09 | 2019-04-30 | 山东铂源药业有限公司 | Compound (E) -3-(1- methylpyrrolidin- 2- yl)-acrylic acid hydrochloride and synthetic method |
| CN110960529A (en) * | 2018-09-30 | 2020-04-07 | 江苏恒瑞医药股份有限公司 | Tyrosine kinase inhibitor bulk drug with reduced toxic impurity content |
| CN111138414A (en) * | 2018-11-05 | 2020-05-12 | 江苏恒瑞医药股份有限公司 | Crystal form of tyrosine kinase inhibitor and preparation method thereof |
| TW202115027A (en) * | 2019-08-30 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | Tyrosine kinase inhibitor with low impurity content |
| CN112625025B (en) * | 2020-12-31 | 2022-03-29 | 河南省医药科学研究院 | Pyridyl-substituted quinoline derivatives and preparation method and use thereof |
| CN112759583B (en) * | 2020-12-31 | 2022-10-11 | 河南省医药科学研究院 | Quinoline derivative containing furyl and preparation method and application thereof |
| CN114890930A (en) * | 2022-04-18 | 2022-08-12 | 重庆医药高等专科学校 | Synthesis method of pyrroltinib intermediate (R, E) -3- (1-methylpyrrolidine-2-yl) acrylic acid hydrochloride |
| CN114920683B (en) * | 2022-06-24 | 2024-03-26 | 苏州富士莱医药股份有限公司 | Preparation method of Boc-prolyl aldehyde and (R, E) - (1-methylpyrrolidin-2-yl) acrylic acid |
| CN115073344B (en) * | 2022-06-24 | 2024-03-26 | 苏州富士莱医药股份有限公司 | Preparation method and application of R- (1-tert-butyloxycarbonyl pyrrolidine-2-yl) acrylic acid |
| WO2024187321A1 (en) * | 2023-03-10 | 2024-09-19 | 甫康（上海）健康科技有限责任公司 | Pharmaceutical composition containing egfr inhibitor, and preparation method therefor and use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0179072B1 (en) * | 1992-04-07 | 1999-03-20 | 알렌 제이. 스피겔 | Indole derivatives as 5-hti agonists |
| US5599902A (en) * | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| CL2004000016A1 (en) * | 2003-01-21 | 2005-04-15 | Wyeth Corp | 4-AMINO-2-BUTENOYL CHLORIDE COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME; PROCEDURE TO PREPARE SUCH COMPOUND, USEFUL AS INTERMEDIARY IN THE SYNTHESIS OF INHIBITING COMPOUNDS OF PROTEIN QUINASA TIROSINA. |
| US7399865B2 (en) * | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| CN101128425B (en) * | 2005-02-25 | 2012-12-26 | 泰特拉洛吉克药业公司 | Dimeric IAP inhibitors |
| AR053364A1 (en) | 2005-04-20 | 2007-05-02 | Smithkline Beecham | COMPOSITE OF 1H-IMIDAZO 84,5-C) PIRIDIN -2- ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCESS TO PREPARE IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT FOR TREATMENT OF CANCER OR ARTHRITIS |
| AU2006249596A1 (en) * | 2005-05-25 | 2006-11-30 | Wyeth | Methods of synthesizing 6-alkylaminoquinoline derivatives |
| JP2007084530A (en) * | 2005-08-22 | 2007-04-05 | Sankyo Co Ltd | Pharmaceutical composition containing indanol derivative |
| WO2010048477A2 (en) | 2008-10-24 | 2010-04-29 | Wyeth Llc | Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates |
| CN102020639A (en) * | 2009-09-14 | 2011-04-20 | 上海恒瑞医药有限公司 | 6-amido quinazoline or 3-cyano quinoline derivative, preparation method thereof and application of derivative to medicament |
| WO2011043817A1 (en) * | 2009-10-07 | 2011-04-14 | Cornell University | Coferons and methods of making and using them |
| US8735409B2 (en) * | 2009-12-21 | 2014-05-27 | Qiang Zhang | Quinazoline derivatives |
| GB0922302D0 (en) * | 2009-12-22 | 2010-02-03 | Imp Innovations Ltd | Compounds |
| CN102382106A (en) * | 2010-08-30 | 2012-03-21 | 黄振华 | Aniline substituted quinazoline derivative |
| CN102675287A (en) | 2011-03-11 | 2012-09-19 | 江苏恒瑞医药股份有限公司 | Pharmaceutically acceptable salts of (E)-N-(4-((3-chloro-4-(2-pyridyl methoxy) phenyl) amino)-3-cyano-7-ethyoxyl-6-quinolyl)-3-((2R)-1-methyl pyrrolidine-2-propyl)-2-acrylamide, preparation method and application of salts in medicines |
| CN104203242B (en) | 2012-04-04 | 2017-03-15 | 杭州德润玉成生物科技有限公司 | Substituted quinolines as Bruton's tyrosine kinase inhibitors |
| TWI609012B (en) * | 2013-04-28 | 2017-12-21 | 廣東東陽光藥業有限公司 | Aminoquinazoline derivatives and their salts and methods of use thereof |
| WO2015028409A1 (en) * | 2013-08-27 | 2015-03-05 | Bayer Pharma Aktiengesellschaft | 6,7-dihydro-5h-benzo[7]annulene derivatives, method for the preparation thereof, pharmaceutical preparations comprising them, and the use thereof for producing medicaments |
| CN105330646B (en) * | 2015-12-04 | 2019-05-24 | 上海勋和医药科技有限公司 | A kind of preparation method of antineoplastic maleic acid linatinib |
-
2017
- 2017-04-27 BR BR112018071617-0A patent/BR112018071617A2/en not_active Application Discontinuation
- 2017-04-27 TW TW106114079A patent/TWI739825B/en not_active IP Right Cessation
- 2017-04-27 EP EP17788792.4A patent/EP3447051B1/en active Active
- 2017-04-27 PL PL17788792T patent/PL3447051T3/en unknown
- 2017-04-27 ES ES17788792T patent/ES2903416T3/en active Active
- 2017-04-27 CA CA3021471A patent/CA3021471A1/en active Pending
- 2017-04-27 WO PCT/CN2017/082164 patent/WO2017186140A1/en not_active Ceased
- 2017-04-27 US US16/094,278 patent/US10793548B2/en not_active Expired - Fee Related
- 2017-04-27 HU HUE17788792A patent/HUE057402T2/en unknown
- 2017-04-27 DK DK17788792.4T patent/DK3447051T3/en active
- 2017-04-27 CN CN201780004193.XA patent/CN108290867B/en active Active
- 2017-04-27 JP JP2018552751A patent/JP6947749B2/en not_active Expired - Fee Related
- 2017-04-27 PT PT177887924T patent/PT3447051T/en unknown
-
2020
- 2020-08-28 US US17/005,489 patent/US11198683B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019520305A (en) | 2019-07-18 |
| EP3447051B1 (en) | 2021-12-15 |
| US10793548B2 (en) | 2020-10-06 |
| ES2903416T3 (en) | 2022-04-01 |
| BR112018071617A2 (en) | 2019-02-19 |
| WO2017186140A1 (en) | 2017-11-02 |
| JP6947749B2 (en) | 2021-10-13 |
| DK3447051T3 (en) | 2022-01-17 |
| HUE057402T2 (en) | 2022-05-28 |
| US20190127350A1 (en) | 2019-05-02 |
| CN108290867B (en) | 2022-02-08 |
| EP3447051A4 (en) | 2019-11-27 |
| TW201738236A (en) | 2017-11-01 |
| US11198683B2 (en) | 2021-12-14 |
| CN108290867A (en) | 2018-07-17 |
| EP3447051A1 (en) | 2019-02-27 |
| CA3021471A1 (en) | 2017-11-02 |
| PT3447051T (en) | 2022-01-06 |
| TWI739825B (en) | 2021-09-21 |
| US20200392111A1 (en) | 2020-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279258B (en) | Tyrosine kinase inhibitors | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| HUE057402T2 (en) | Method for preparing tyrosine kinase inhibitor and derivative thereof | |
| IL275207A (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| PL3218378T3 (en) | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | |
| SG11202004918XA (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
| IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
| ZA201700021B (en) | Alk kinase inhibitor, and preparation method and use thereof | |
| IL304547A (en) | 3-substituted benzamide derivatives as kinase inhibitors | |
| PL3689351T3 (en) | Quinoline derivative and application thereof as tyrosine kinase inhibitor | |
| ZA201802141B (en) | Egfr kinase inhibitor and preparation method and use thereof | |
| ZA201808014B (en) | Adenine derivatives as protein kinase inhibitors | |
| ZA201808238B (en) | Certain protein kinase inhibitors | |
| IL247867A0 (en) | Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| EP3699177A4 (en) | Preparation method for tyrosine kinase inhibitor and intermediate thereof | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| HK40029221A (en) | Kinase inhibitors and methods for making and using | |
| GB201519381D0 (en) | Kinase inhibitors |